Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

HLA class I allele associations with HCV genetic variants in patients with chronic HCV genotypes 1a or 1b infection.

Lange CM, Roomp K, Dragan A, Nattermann J, Michalk M, Spengler U, Weich V, Lengauer T, Zeuzem S, Berg T, Sarrazin C.

J Hepatol. 2010 Dec;53(6):1022-8. doi: 10.1016/j.jhep.2010.06.011. Epub 2010 Aug 3.

PMID:
20800922
2.

Genetic variability of hepatitis C virus non-structural protein 3 and virus-specific CD8+ response in patients with chronic hepatitis C.

López-Labrador FX, He XS, Berenguer M, Cheung RC, González-Candelas F, Wright TL, Greenberg HB.

J Med Virol. 2004 Apr;72(4):575-85.

PMID:
14981760
3.

Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection.

Gaudieri S, Rauch A, Park LP, Freitas E, Herrmann S, Jeffrey G, Cheng W, Pfafferott K, Naidoo K, Chapman R, Battegay M, Weber R, Telenti A, Furrer H, James I, Lucas M, Mallal SA.

J Virol. 2006 Nov;80(22):11094-104. Erratum in: J Virol. 2007 Aug;81(16):8846-8.

5.

Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy.

Vuillermoz I, Khattab E, Sablon E, Ottevaere I, Durantel D, Vieux C, Trepo C, Zoulim F.

J Med Virol. 2004 Sep;74(1):41-53.

PMID:
15258967
6.

Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy.

Sarrazin C, Bruckner M, Herrmann E, Rüster B, Bruch K, Roth WK, Zeuzem S.

Virology. 2001 Oct 10;289(1):150-63.

7.
8.

Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.

Hayashi K, Katano Y, Kuzuya T, Tachi Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Ishikawa T, Nakano I, Urano F, Yoshioka K, Toyoda H, Kumada T, Goto H.

J Med Virol. 2012 Mar;84(3):438-44. doi: 10.1002/jmv.23207.

PMID:
22246829
9.

Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure.

Rauch A, James I, Pfafferott K, Nolan D, Klenerman P, Cheng W, Mollison L, McCaughan G, Shackel N, Jeffrey GP, Baker R, Freitas E, Humphreys I, Furrer H, Günthard HF, Hirschel B, Mallal S, John M, Lucas M, Barnes E, Gaudieri S.

Hepatology. 2009 Oct;50(4):1017-29. doi: 10.1002/hep.23101.

PMID:
19670417
10.

Variations in the viral NS5B region in Japanese patients with chronic hepatitis C virus genotype 1b infection. No specific amino acid substitution was identified as determinants of treatment response to interferon/ribavirin combination therapy.

Sugihara K, Orito E, Tanaka Y, Kato T, Lau JY, Ohno T, Hayashi K, Ogino M, Hirashima N, Sakakibara K, Mizuno Y, Kato H, Suzuki S, Ueda R, Mizokami M.

Intervirology. 2006;49(6):319-26. Epub 2006 Aug 21.

PMID:
16926544
11.

Relation between viral fitness and immune escape within the hepatitis C virus protease.

Söderholm J, Ahlén G, Kaul A, Frelin L, Alheim M, Barnfield C, Liljeström P, Weiland O, Milich DR, Bartenschlager R, Sällberg M.

Gut. 2006 Feb;55(2):266-74. Epub 2005 Aug 16.

12.

Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients.

Sarrazin C, Susser S, Doehring A, Lange CM, Müller T, Schlecker C, Herrmann E, Lötsch J, Berg T.

J Hepatol. 2011 Mar;54(3):415-21. doi: 10.1016/j.jhep.2010.07.041. Epub 2010 Sep 22.

PMID:
21112657
13.

Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes.

Kim AY, Kuntzen T, Timm J, Nolan BE, Baca MA, Reyor LL, Berical AC, Feller AJ, Johnson KL, Schulze zur Wiesch J, Robbins GK, Chung RT, Walker BD, Carrington M, Allen TM, Lauer GM.

Gastroenterology. 2011 Feb;140(2):686-696.e1. doi: 10.1053/j.gastro.2010.09.042. Epub 2010 Sep 24.

14.

Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy.

Kumthip K, Pantip C, Chusri P, Thongsawat S, O'Brien A, Nelson KE, Maneekarn N.

J Viral Hepat. 2011 Apr;18(4):e117-25. doi: 10.1111/j.1365-2893.2010.01379.x. Epub 2010 Oct 19.

PMID:
20955493
15.

Conservation of hepatitis C virus nonstructural protein 3 amino acid sequence in viral isolates during liver transplantation.

Mello IM, Thumann C, Schvoerer E, Soulier E, Pinho JR, Silvestre DA, Queiroz AT, Wolf P, Baumert TF, Keller FS, Pereira CA.

J Viral Hepat. 2009 Oct;16(10):732-7. doi: 10.1111/j.1365-2893.2009.01125.x. Epub 2009 Mar 25.

PMID:
19486468
16.

Impact of sequence variation in a dominant HLA-A*02-restricted epitope in hepatitis C virus on priming and cross-reactivity of CD8+ T cells.

Ziegler S, Skibbe K, Walker A, Ke X, Heinemann FM, Heinold A, Mok JY, van Esch WJ, Yang D, Wölfl M, Timm J.

J Virol. 2014 Oct;88(19):11080-90. doi: 10.1128/JVI.01590-14. Epub 2014 Jul 9.

17.
18.

Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection.

Chambers TJ, Fan X, Droll DA, Hembrador E, Slater T, Nickells MW, Dustin LB, Dibisceglie AM.

J Virol. 2005 Mar;79(5):3071-83.

19.

Quasispecies of hepatitis C virus genotype 1 and treatment outcome with peginterferon and ribavirin.

Jardim AC, Yamasaki LH, de Queiróz AT, Bittar C, Pinho JR, Carareto CM, Rahal P, Mello IM.

Infect Genet Evol. 2009 Jul;9(4):689-98. doi: 10.1016/j.meegid.2008.11.001. Epub 2008 Nov 21.

PMID:
19063998
20.

Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source.

McKiernan SM, Hagan R, Curry M, McDonald GS, Kelly A, Nolan N, Walsh A, Hegarty J, Lawlor E, Kelleher D.

Hepatology. 2004 Jul;40(1):108-14.

PMID:
15239092
Items per page

Supplemental Content

Write to the Help Desk